Lured by high demand, Korean wholesaler smuggled Novo’s obesity drug Saxenda into China
Anti-obesity drug Saxenda has been one of Novo Nordisk’s key growth drivers lately—and apparently, a Korean wholesaler noticed. The pharmaceutical middleman allegedly smuggled the popular drug into China, where it’s not yet approved. Korean regulators are investigating the wholesaler for allegedly hawking Saxenda in China, Korea Biomedical Review reported, citing multiple sources. A Novo spokeswoman confirmed to FiercePharma… Read More »